126 related articles for article (PubMed ID: 38618837)
21. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
22. Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement.
Nieto-Gómez P; Castaño-Amores C; Rodríguez-Delgado A; Álvarez-Sánchez R
Eur J Health Econ; 2024 Mar; 25(2):257-267. PubMed ID: 36995531
[TBL] [Abstract][Full Text] [Related]
23. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
24. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.
Wei Y; Zhang Y; Xu Z; Wang G; Zhou Y; Li H; Shi L; Naci H; Wagner AK; Guan X
Lancet Reg Health West Pac; 2024 Apr; 45():101055. PubMed ID: 38590780
[TBL] [Abstract][Full Text] [Related]
25. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
26. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
[No Abstract] [Full Text] [Related]
27. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
Front Public Health; 2022; 10():921093. PubMed ID: 35844892
[TBL] [Abstract][Full Text] [Related]
28. Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021.
Huang Y; Xiong W; Zhao J; Li W; Ma L; Wu H
J Clin Epidemiol; 2023 May; 157():74-82. PubMed ID: 36905971
[TBL] [Abstract][Full Text] [Related]
29. [Duration of the Reimbursement Process in Spain for Innovative Drugs Approved by the European Medicines Agency during the Period 2008-2013].
Pinyol C; Valmaseda A; Gómez-Ulloa D; Solozabal M; Restovic G
Rev Esp Salud Publica; 2015 Apr; 89(2):189-200. PubMed ID: 26121628
[TBL] [Abstract][Full Text] [Related]
30. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries.
Mills M; Michaeli D; Miracolo A; Kanavos P
BMC Health Serv Res; 2023 Feb; 23(1):150. PubMed ID: 36782175
[TBL] [Abstract][Full Text] [Related]
31. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
32. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
[TBL] [Abstract][Full Text] [Related]
33. Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.
Zhang Y; Hueser HC; Hernandez I
J Manag Care Spec Pharm; 2017 Feb; 23(2):247-254. PubMed ID: 28125371
[TBL] [Abstract][Full Text] [Related]
34. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
Persson U; Norlin JM
Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
[TBL] [Abstract][Full Text] [Related]
36. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
37. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
38. Review time of oncology drugs and its underlying factors: an exploration in China.
Zhu X; Liu B
Front Pharmacol; 2023; 14():1151784. PubMed ID: 38027001
[No Abstract] [Full Text] [Related]
39. Policy Updates on Access to and Affordability of Innovative Medicines in China.
Liu GG; Wu J; He X; Jiang Y
Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
[TBL] [Abstract][Full Text] [Related]
40. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
Michaeli DT; Mills M; Kanavos P
Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
